HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study - PubMed (original) (raw)

. 2005 Sep-Oct;8(5):525-32.

doi: 10.1007/s10024-005-0044-5. Epub 2005 Oct 5.

Affiliations

• PMID: 16211448
• DOI: 10.1007/s10024-005-0044-5

HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study

Gino R Somers et al. Pediatr Dev Pathol. 2005 Sep-Oct.

Abstract

The HER2 gene, located on 17q, encodes a 185-kD transmembrane tyrosine kinase receptor. Amplification of this gene with overexpression of the gene product occurs in about 30% of cases of breast cancer and is considered to be a poor prognostic indicator for this tumor. Results for HER2 expression in osteosarcoma are controversial, with some studies reporting up to 61% of positive cases and others reporting only negative results. Further, expression of HER2 is reported to be a favorable prognostic indicator by some groups and unfavorable by others. The present study used tissue microarrays containing 34 samples of osteosarcoma from 18 patients to analyze HER2 expression by immunohistochemistry and gene copy number by chromogenic in situ hybridization. The microarray included 13 pretreatment biopsies, 11 posttreatment resection specimens, and 10 resected metastases and comprised 18 osteoblastic, 6 chondroblastic, 5 fibroblastic, and 5 mixed subtypes. HER2 protein expression was seen in 4 of 34 (12%) tumor samples that originated from 2 of 18 patients (11%). The staining pattern was consistently weak and focal, and immunohistochemical overexpression of the HER2 protein, defined as complete membrane positivity, was never observed. Further, the presence of HER2 gene amplification was not detected in any osteosarcoma by chromogenic in situ hybridization. Therefore, therapies based on antibodies directed against the HER2 protein are unlikely to have much value in the treatment of pediatric osteosarcomas. From a technical standpoint, this study also demonstrates the value of tissue microarrays in screening tumors at the protein and gene levels using conventional light microscopy.

PubMed Disclaimer

Similar articles

• Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas.
  Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PM, Taminiau AH, Nooij M, Egeler RM, Hogendoorn PC. Anninga JK, et al. Eur J Cancer. 2004 May;40(7):963-70. doi: 10.1016/j.ejca.2003.10.025. Eur J Cancer. 2004. PMID: 15093570
• HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique.
  Langner C, Gross C, Rehak P, Ratschek M, Rüschoff J, Zigeuner R. Langner C, et al. Urology. 2005 Jan;65(1):176-80. doi: 10.1016/j.urology.2004.08.025. Urology. 2005. PMID: 15667899
• [HER2 gene amplification assay: is CISH an alternative to FISH?].
  Denoux Y, Arnould L, Fiche M, Lannes B, Couturier J, Vincent-Salomon A, Penault-Llorca F, Antoine M, Balaton A, Baranzelli MC, Becette V, Bellocq JP, Bibeau F, Ettore F, Fridman V, Gnassia JP, Jacquemier J, MacGrogan G, Mathieu MC, Migeon C, Rigaud C, Roger P, Sigal-Zafrani B, Simony-Lafontaine J, Trassard M, Treilleux I, Verriele V, Voigt JJ; Groupe d'Etude des Facteurs Pronostiques en Immunohistochimie dans le Cancer du Sein. Denoux Y, et al. Ann Pathol. 2003 Dec;23(6):617-22. Ann Pathol. 2003. PMID: 15094603 Review. French.
• Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
  Serrano-Olvera A, Dueñas-González A, Gallardo-Rincón D, Candelaria M, De la Garza-Salazar J. Serrano-Olvera A, et al. Cancer Treat Rev. 2006 May;32(3):180-90. doi: 10.1016/j.ctrv.2006.01.001. Epub 2006 Feb 17. Cancer Treat Rev. 2006. PMID: 16483720 Review.

Cited by

• Promise and Challenges of T Cell Immunotherapy for Osteosarcoma.
  Park JA, Cheung NV. Park JA, et al. Int J Mol Sci. 2023 Aug 7;24(15):12520. doi: 10.3390/ijms241512520. Int J Mol Sci. 2023. PMID: 37569894 Free PMC article. Review.
• Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors.
  Boccalatte F, Mina R, Aroldi A, Leone S, Suryadevara CM, Placantonakis DG, Bruno B. Boccalatte F, et al. Cancers (Basel). 2022 Oct 18;14(20):5108. doi: 10.3390/cancers14205108. Cancers (Basel). 2022. PMID: 36291891 Free PMC article. Review.
• GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
  Park JA, Cheung NV. Park JA, et al. J Hematol Oncol. 2020 Dec 10;13(1):172. doi: 10.1186/s13045-020-01012-y. J Hematol Oncol. 2020. PMID: 33303017 Free PMC article.
• Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.
  Lilienthal I, Herold N. Lilienthal I, et al. Int J Mol Sci. 2020 Sep 19;21(18):6885. doi: 10.3390/ijms21186885. Int J Mol Sci. 2020. PMID: 32961800 Free PMC article. Review.
• Identification of Lysosome-Associated Protein Transmembrane-4 as a Novel Therapeutic Target for Osteosarcoma Treatment.
  Wang ZX, Guo MY, Ren J, Li GS, Sun XG. Wang ZX, et al. Orthop Surg. 2020 Aug;12(4):1253-1260. doi: 10.1111/os.12692. Epub 2020 Jun 18. Orthop Surg. 2020. PMID: 32558212 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal